Despite the fact that some studies have elucidated how deletions of the leptin pathway in a specific way, mainly in the CNS, can deregulate lipid and glucose metabolism in the liver, we would like to call attention to more data are needed using better conditional or inducible transgenic animal models to get specific insight into the molecular mechanism of leptin action in the context of liver diseases. The gene discussed is LEP; the disease is liver disorder.